SXLV:LSE:LSE-SPDR S&P U.S. Health Care Select Sector UCITS (USD)

ETF | Others |

Last Closing

USD 42.39

Change

0.00 (0.00)%

Market Cap

USD 0.38B

Volume

9.40K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 636.40B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 330.91B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B

ETFs Containing SXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.34% 48% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.34% 48% F 52% F
Trailing 12 Months  
Capital Gain 6.74% 45% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.74% 44% F 54% F
Trailing 5 Years  
Capital Gain 69.29% 83% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.29% 81% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 11.46% 76% C+ 76% C+
Dividend Return 11.46% 76% C+ 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.60% 65% D 78% C+
Risk Adjusted Return 108.18% 99% N/A 99% N/A
Market Capitalization 0.38B 65% D 56% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike